John McGrane

John McGrane

Auto-generated profile, based on publicly available information

John McGrane

Royal Cornwall Hospital NHS Trust, Truro, UK

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
JMJohn M. McGrane
John M. McGrane
DHDavid J. Humes
David J. Humes
AAAustin G. Acheson
Austin G. Acheson
FMFiona Minear
Fiona Minear
JWJames M.D. Wheeler
James M.D. Wheeler
CWCatherine J. Walter
Catherine J. Walter


11 March 2024 in ESMO Real World Data and Digital Oncology
Verified
Journal Article
Open access
RFR. Frazer
R. Frazer
JMJ.M. McGrane
J.M. McGrane
ACA. Challapalli
A. Challapalli
GRG. Ratnayake
G. Ratnayake
JMJ. Malik
J. Malik
ABA. Bahl
A. Bahl
The introductions of immunotherapy and first-line combinations have led to major changes in systemic anti-cancer treatment (SACT) options and outcomes in metastatic renal cell carcinoma (mRCC). To evaluate current real-world UK practice in the immunotherapy era looking at survival outcomes by International Metastatic RCC Database Consortium (IMDC) risk stratification and prescribing patterns/drop-off rates of SACT in mRCC. This is a retrospective multi-institutional cohort of SACT patients for mRCC at 17 centres across the UK from 1 January 2018 and 30 June 2021. Patient characteristics, IMDC risk group and lines of therapy were recorded. Overall survival (OS) and progression-free survival (PFS) for IMDC groups were analysed. Of the 1319 patients, 22.3%, 52.7% and 24.3% were IMDC group favourable, intermediate and poor, respectively. Across all risk groups and censoring for patients who have not progressed on their current therapy line, 59.2%, 23.5% and 6.3 % of first-line patients with SACT received second-, third- and fourth-line treatments; 40.1%, 33.2% and 44.2%, respectively, did not receive immunotherapy at any stage in their treatment. Median PFS was statistically different by IMDC risk group: 14.0, 8.2 and 4.8 months in the favourable, intermediate and poor groups (P < 0.0001). Median OS was statistically different by risk group and were 40.9, 24.1 and 10.2 months for favourable, intermediate and poor risk groups, respectively. The majority of patients receive only one or two treatment lines in mRCC. The IMDC prognostic risk groups remain valid in the immunotherapy era. A significant group of patients in this cohort did not receive immunotherapy at any stage.

15 June 2017 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
ASA. Smits
A. Smits
JMJ. McGrane
J. McGrane
ALAlberto de Barros Lopes
Alberto de Barros Lopes
EKE. Kent
E. Kent
RBR. Bekkers
R. Bekkers
KGK. Galaal
K. Galaal

21 June 2024 in Cancer Medicine
Verified
Journal Article
Open access
JMJohn McGrane
John McGrane
RFRicky Frazer
Ricky Frazer
ACAmarnath Challapalli
Amarnath Challapalli
GRGihan Ratnayake
Gihan Ratnayake
ZBZhaung Boh
Zhaung Boh
ABAmit Bahl
Amit Bahl
Introduction: Clinical trials show improved progression‐free survival (PFS) and overall survival (OS) in first‐line metastatic renal cell carcinoma (mRCC) patients with immunotherapy containing systemic anti‐cancer therapies (SACT). However, in the favourable international metastatic renal cell cancer database consortium (IMDC) group there is no trial evidence for OS benefit despite clear PFS improvement when comparing anti‐VEGF tyrosine kinase inhibitor (TKI) monotherapy and (immunotherapy and TKI) IO/TKI combinations. Objective: To assess the impact of first‐line SACT choice on the clinical outcomes of PFS and OS in mRCC. To evaluate this impact of initial SACT for allcomers and the favourable IMDC group. Methods: A multicentre retrospective review of patients who started SACT for mRCC (01/01/2018–30/06/2021) at 17 UK NHS trusts. Patient demographics and IMDC group were analysed. Survival data were compared using Kaplan–Meier curves, and the statistical significance of differences in outcome between the groups was assessed with the log‐rank test. Univariable and multivariable Cox proportional hazard modelling estimate the hazard ratios (HRs) for survival outcomes associated with IMDC and treatment subtype. Results: One thousand three hundred and nineteen patients were identified with a median age of 64. 294 (22.3%), 695 (52.7%) and 321 (24.3%) were IMDC group favourable, intermediate and poor, respectively. 311 (23.6%), 197 (14.9%) and 778 (59%) patients received checkpoint inhibitor and anti‐CTLA4 monoclonal antibody (IO/IO), IO/TKI and TKI first‐line SACT across all IMDC groups. Significant PFS improvement favouring IO/TKI versus TKI was demonstrated in allcomers HR = 0.61. In the favourable risk group, Log rank testing demonstrated a significant benefit for IO/TKI over TKI for PFS (HR = 0.60, 95% CI [0.39, 0.91]) and OS (HR = 0.42, 95% CI [0.18, 0.99]). Conclusion: In this real‐world evidence cohort, we have shown OS and PFS benefit with IO/TKI versus TKI in the favourable IMDC risk group. This has not been previously reported from trial outcomes and would support use of front‐line IO/TKI in mRCC favourable risk patients.

9 December 2022 in Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HDH. Donkers
H. Donkers
CRC. Reijnen
C. Reijnen
KGK. Galaal
K. Galaal
MLM.S. Lombaers
M.S. Lombaers
MSM. Snijders
M. Snijders
JMJ. McGrane
J. McGrane